Pharma BD Deal Intelligence
A 2007 antibody discovery alliance built on Regeneron's VelocImmune technology that nobody expected would produce a $13B/year franchise. Dupixent emerged from this platform and redefined atopic dermatitis treatment, making this one of the highest-ROI partnerships in biopharma history.
Most productive pharma partnership in history: Dupixent $13B+ mega-blockbuster
Full analysis, sources & comparables →Sanofi-Aventis (now Sanofi) and Regeneron established a broad antibody discovery and development alliance using Regeneron's proprietary VelocImmune technology. The original 2007 agreement gave Sanofi global commercialization rights to antibodies discovered through the alliance, with Regeneron receiving funded research plus milestone and royalty payments. The collaboration generated dupilumab (Dupixent), which became a blockbuster ($10B+ annual revenue). The deal was restructured multiple times, most significantly in 2015 when Sanofi paid $640M upfront to restructure profit-sharing terms.
16.5M US cases/yr · $2.0B Global Atopic Dermatitis Market (2007)
Atopic dermatitis is a chronic, relapsing inflammatory skin disease affecting roughly 7% of US adults and up to 13% of US children. Pathogenesis involves impaired skin barrier function, Th2-skewed immune activation with elevated IL-4 and IL-13 signaling, and pruritus-driven scratching that further damages the barrier. Moderate-to-severe disease causes substantial sleep, work, and quality-of-life impairment and carries increased risk of other atopic comorbidities including asthma, allergic rhinitis, and food allergy.
The 2007 discovery alliance gave Sanofi global commercialization rights to antibodies from Regeneron's VelocImmune platform. Dupixent (dupilumab, anti-IL-4/IL-13) emerged as the flagship product, becoming a $13B+ blockbuster across atopic dermatitis, asthma, and CRSwNP. The alliance also produced Kevzara and Libtayo.
Sanofi SA closes co-development of Regeneron Pharmaceuticals, Inc. for $1.0B, establishing strategic position and initiating integration.
Sanofi-Regeneron VelocImmune collaboration produced Dupixent ($13B+ annual sales) one of the most successful pharma partnerships ever despite governance tensions.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Regeneron Pharmaceuticals, Inc. (this deal) | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
| Sanofi SA / Protein Sciences Corp. | 2017 | $650M | 72 |
← Browse all deals · How we score deals
More: 2007 deals · Sanofi SA deals · Dermatology deals